In-vitro and in-vivo Anticoccidial Activities of Berberine against Murine *Eimeria papillata* Infection

Nour E. Sherif¹, Mahmoud S. Metwaly¹,², Saleh Al-Quraishy² and Mohamed A. Dkhil²,³*

¹Department of Zoology, Faculty of Science, Suez Canal University, Ismailia, Egypt.
²Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
³Department of Zoology and Entomology, Faculty of Science, Helwan University, Cairo, Egypt.

(Received: 15 March 2014; accepted: 14 May 2014)

Intestinal Eimerian infections are considered to be one of the most highly distributed protozoan parasitic infections among farms and domestic animals, and cause huge economic losses in the field of animal farming and meat production. All recent trends to fight infectious diseases depend upon using treatment of natural origins instead of synthetic drug therapy. Berberine is a plant derived isoquinoline alkaloid with wide spectrum pharmacological and antimicrobial activities. The current study was designed to elucidate the *in-vitro* and *in-vivo* anticoccidial activities of berberine chloride against murine intestinal *Eimeria papillata* infection. *In-vitro* measurements showed that berberine could significantly reduce the viability and sporulation percent of *E. papillata* unsporulated oocyst. In addition, berberine showed a pronounced *in-vivo* anticoccidial activity as revealed by reducing the number of zygots and developing oocysts within intestinal villi by about 90% and that of schizonts and gamonts by 58% and 30% respectively. Moreover, berberine treatment of *E. papillata* infected mice showed a great increase in the total antioxidant capacity within jejunum tissue. Finally, the results of the study proved both *in-vitro* and *in-vivo* anticoccidial activities of berberine chloride against the murine intestinal *E. papillata* infection, and could effectively correct the induced disruption in the antioxidant capacity within jejunum tissue by such infection.

Key word: *Eimeria papillata*, berberine, anticoccidial, *in-vitro*, *in-vivo*.

Coccidiosis is a cosmopolitan disease caused by the protozoan parasite of the genus *Eimeria*, and is considered to be the most important parasitic disease of veterinary importance throughout the world. It affects animal health and production and induces huge economic losses in the field of animal farming, milk and meat production¹. The infection with Eimerian parasites greatly affect growth and food metabolism and cause loss of animal communities²,³ and is characterized by weight depression, severe diarrhea, mucoid and bloody stool and leads finally to dehydration⁴,⁵,⁶. Such signs are accompanied by damaged intestinal wall which in turn leads to disturbance in food digestion, absorption and metabolism⁷,⁸.

Natural products have been used for dietary therapy for several millennia, and some of them allegedly exhibit significant antioxidant activity. Recent studies have showed that a number of plant products, including polyphenols and flavonoids and various plant extracts, exerted an antioxidant action⁹.

Berberine is an isoquinoline alkaloid, present in roots and stem-bark of clinically important medicinal plants⁹. Berberine based formulations, are widely used in traditional systems
of medicine\textsuperscript{10}. It has demonstrated wide range of pharmacological activities and is not considered to be toxic at doses used in clinical situations, nor has it been shown to be cytotoxic or mutagenic\textsuperscript{11}. The current study aims to test the role of berberine as an anticoccidial drug using both invitro and invivo measurements.

**MATERIALS AND METHODS**

**In-vitro anticoccidial activities of berberine**

A self-healing strain of *E. papillata* was kindly provided by Prof. Mehlhorn (Heinrich Heine University, Duesseldorf, Germany). Several passage processes of *E. papillata* were performed in laboratory mice, followed by oocyst collection from faeces by concentration using floatation technique. Oocysts then were washed several times and suspended in normal saline solution. Using small petri dishes, oocysts were divided into six plates. Three plates were mixed with 0.5% berberine chloride solution and served as BBR-treated oocysts. The other plates were mixed with normal saline and served as control untreated oocysts. Both groups were incubated at 37°C overnight.

Small volumes from all plates were mixed with trypan blue stain for five min and examined under microscope for viability of both control untreated and BBR-treated oocysts. Remaining parts of oocysts were concentrated by centrifugation and mixed with 2.5% potassium dichromate solution and allowed for sporulation process. After six days, the percentage of sporulated oocysts was calculated in both groups.

**In-vivo anticoccidial activities of berberine**

Freshly prepared sporulated oocysts of *E. papillata* were washed several times with sterile saline and then surface-sterilized with sodium hypochlorite, and washed at least four times with sterile saline before oral inoculation as described by Schito and Barta (1997)\textsuperscript{12}. These oocysts were used to inoculate mice by oral gavaging each mouse with 1.5×10\textsuperscript{3} sporulated *E. papillata* oocysts suspended in 100 µl sterile saline.

Berberine chloride was purchased from Sigma Company (St Louis, MO, USA). Each mouse was orally inoculated with 10 mg/Kg berberine chloride. The used dose is in agreement with previous studies on other intestinal protozoan infections and toxicity measurements\textsuperscript{13,14}.

Male Swiss albino mice (9-11 weeks) were randomly divided into three groups. The first group received saline and served as control uninfected animals. The second and third groups were orally infected with 1.5×10\textsuperscript{3} sporulated *E. papillata* oocysts. The 3rd group was treated with a daily dose of berberine chloride for five successive days. The experiments were approved by state authorities and followed Saudi Arabian rules for animal protection. Weight change of mice was recorded during the experimental time and at the end of the experiment.

On day 5 p.i., all animals were killed by cervical dislocation and dissected. Pieces of jejunum were freshly prepared, fixed in 10% neutral buffered formalin, and then embedded in paraffin. Sections were cut and stained with hematoxylin and eosin. Number of individual parasitic stages of zygotes and developing oocysts, schizonts and gamonts were determined within ten intestinal crypt villi.

Jejunal homogenate was assayed for total antioxidant capacity using a colorimetric method based on the activity of total antioxidants within jejunum tissue to certain amounts of exogenously added $H_2O_2$. Residual amounts of $H_2O_2$ are enzymatically determined yielding colored products\textsuperscript{15}.

**Statistical analysis**

One-way ANOVA was carried out, and the statistical comparisons among the groups were performed with Duncan’s t-test using a statistical package program (SPSS version 17.0). P values are d” 0.05 was considered as significant for all statistical analysis in this study.

**RESULTS AND DISCUSSION**

Berberine showed an in-vivo anticoccidial activity against unsporulated *E. papillata* oocysts. Trypan blue stained oocysts (Fig 1) showed a decrease in the number of viable *E. papillata* unsporulated oocysts after berberine incubation. In addition, upon berberine incubation with unsporulated oocysts leads to decreasing the percentage of sporulated oocysts from 94±2 to 68±8% after incubation with potassium dichromate solution for six days (Fig 2).

Evaluating individual stage score of *E.
papillata infected jejunum tissue and after berberine treatment of infected mice showed that upon berberine treatment the number of intracellular schizonts per ten villous crypt unit (VCU) was decreased from 37.3 to 15.9 stage/10 VCU, and that of zygots and developing oocysts was decreased from 25.3 to 2.6. In addition, the number of intracellular gamont stages was decreased from 26.7±2.8 to 19±2.7 stage/10 VCU upon berberine treatment of E. papillata-infected mice (Table 1, Fig 3).

Previous studies proved the strong activity of berberine salt, extract, or derivatives against other genera of intestinal protozoan infections. It had an in-vitro inhibition of the growth of Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis. All parasites exhibited morphological changes after exposure to berberine sulfate. Berberine also had an in vitro amoebicidal effect on E. histolytica and causes degeneration and lysis of the trophozoite forms. It inhibited the growth of Trichomonas vaginalis via the formation of large autophagic vacuoles that result in lysis of the trophozoite forms. In addition, berberine has an in-vitro and in-vivo anti-protozoan activity against blood parasites as Leishmania, Malaria and Trypanosoma. It also exerts anti-leishmanial effects via inhibition of multiplication, respiration, and macromolecular biosynthesis of amastigote forms of the parasite, interfered with the nuclear DNA of the promastigote form, and inhibited organism maturation. BBR was found to have strong anti-malarial activities. It has a high clearance rate of asexual parasitemia. It inhibits telomerase activity of P. falciparum in a dose dependent manner. It interacts with plasmodium DNA effectively. Moreover, administration of berberine showed a significant prolongation of the lives of rats infected with Trypanosoma equiperdum. Berberine was found to induce programmed cell death in blood stream forms of Trypanosomes (Trypanosoma brucei). It exerts its action via DNA intercalation, protein biosynthesis inhibition and cellular cytotoxicity of parasitic forms. In addition, it was found that berberine and its derivatives have cytotoxic activities against Toxoplasma gondii parasite and inhibits the growth and replication of tachyzoite forms of the parasite.

**Table 1.** Berberine induced alterations in the number of developmental stages per ten VCU of E. papillata on day 5 p.i

<table>
<thead>
<tr>
<th></th>
<th>Oocyst &amp; Zygote</th>
<th>Schizonts</th>
<th>Gamonts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Un-infected (- Berberine)</td>
<td>0±0</td>
<td>0±0</td>
<td>0±0</td>
</tr>
<tr>
<td>Infected (- Berberine)</td>
<td>25.3±3.7</td>
<td>37.3±5.2</td>
<td>26.7±2.8</td>
</tr>
<tr>
<td>Infected (+Berberine)</td>
<td>2.6±0.5*</td>
<td>15.9±3.2*</td>
<td>19±2.7*</td>
</tr>
</tbody>
</table>

Values are Means ± SD. *P ≤ 0.05 significance for - Berberine vs. +Berberine

**Fig. 1.** Control (A) and tryban blue (B) stained unsporulated Eimeria papillata oocysts. Scale bar = 25 µm
Current results showed that *E. papillata* infection induced severe disturbance in jejunal antioxidant capacity as revealed by decreasing total antioxidant capacity (TAC) from 2.8±0.35 to 1.2±0.16 mM/g (Fig 4). Upon berberine treatment of infected mice TAC within jejunal tissue was significantly reduced to be 2.1±0.4 mM/g (Fig 4). Coccidian parasites of the genus *Eimeria* complete their life cycles within intestinal epithelial cells and is associated with infiltration of inflammatory cells as macrophages, T-cells, neutrophils and mast cells. This leads to initiation of cytotoxic and oxidative damage within infected mucosal tissue leading to their destruction via production of reactive oxygen and nitrogen intermediates, and severe disturbance in the protective antioxidant systems. Berberine was found to have strong antioxidant activities and inhibition of the oxidative damage in different tissues and cell lines. Chemically, it expressed a great capacity for quenching different free radicals as DPPH, $O_2^-$, NO$^-$ and OH$^-$ and also activates the antioxidant enzyme systems of SOD, CAT, GST and GPX, with conservation activities of non-enzymatic antioxidant levels as GSH, Vit C and Vit E.

Finally, it is recommended to use berberine chloride for treatment of Eimerian parasites induced coccidiosis and to enhance the intestinal antioxidant system of infected animals.
ACKNOWLEDGEMENTS

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding this work through Research Group Project number RGP-198.

REFERENCES


J PURE APPL MICROBIO, 8(SPL. EDN.), MAY 2014.